



Chemomab to present at the Citi's 15th Annual BioPharma Virtual Conference

Tel Aviv -September, 2020 -- [Chemomab Ltd.](#), a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that Adi Mor, CEO, will present at the Citi's 15th Annual BioPharma Virtual Conference.

The presentation will be broadcasted live on Tuesday, September 8, 2020 at 08:20 am EST

About Chemomab

[Chemomab](#) is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein [CCL24](#) in promoting fibrosis and inflammation, Chemomab generated CM-101 that is currently in development for the treatment of patients with PSC, systemic sclerosis (SSc) and nonalcoholic steatohepatitis (NASH). During Q3 2020 Chemomab will initiate the first phase 2a clinical trial evaluating the safety and efficacy of CM-101 in subjects with PSC ([SPRING Study](#)).

Chemomab is a privately held company and is supported by strong lead investors that include OrbiMed and Thiel Capital.

About CM-101

Chemomab's [CM-101 Platform](#) is a first-in-class humanized monoclonal antibody designed to bind and block CCL24 activity. CM-101 interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in-vivo, in-vitro and ex-vivo studies, including experimental models of liver, skin and lung fibrosis. CM-101 was found to be safe and well tolerated in phase 1 clinical trials and is currently under clinical development for PSC, SSc NASH. CM-101 hold orphan drug designation from the FDA and EMA for the treatment of PSC and SSc.

Chemomab Contact:

Mr. Sharon Elkobi
VP of Business Development
office@chemomab.com

+972-77-331-0156